Synthesis, 68Ga-Radiolabeling, and Preliminary In Vivo Assessment of a Depsipeptide-Derived Compound as a Potential PET/CT Infection Imaging Agent
Table 2
Organ/tissue concentration and biodistribution of 68Ga-DOTA-TBIA101 in Escherichia coli infected mice.
Organ/tissue
Activity concentration (SUV)
Compound distribution (%ID)
Infected
Healthy control*
Infected
Healthy control
Heart
16 ± 2.2
0.43
9.5
8.9
Lung
0.73 ± 0.03
0.48
0.50
0.50
Liver
25 ± 3.9
14
14
14
Kidneys
59 ± 6.3
35
36
36
Brain
0.90 ± 0.1
0.55
0.55
0.57
Intestine
0.90 ± 0.1
0.54
0.58
0.57
Urinary tract/bladder
34 ± 2.9
20
21
21
Forearm muscle
1.1 ± 0.2
0.58
0.63
0.60
Hind muscle (CL)
1.5 ± 0.3
0.73
0.77
0.76
Hind muscle (E.coli)
1.7 ± 0.3
0.73
0.94
0.76
Hind muscle (CL) to forearm muscle
1.4 ± 0.1
NA
NA
NA
Hind muscle (E.coli) to background ratio
2.3 ± 0.5
NA
NA
NA
Hind muscle (E.coli) to forearm muscle
1.6 ± 0.1
NA
NA
NA
Hind muscle (E.coli) hind muscle (CL)
1.2 ± 0.1
NA
NA
NA
Values expressed as mean ± SEM. E.coli = Escherichia coli 22952 , healthy control , and CL = contralateral. *The SUV values were calculated from the same region of interest area using one healthy animal.
